ReviewCardiology research and practice2020
In-Stent Restenosis and a Drug-Coated Balloon: Insights from a Clinical Therapeutic Strategy on Coronary Artery Diseases.
Review in Cardiology research and practice, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 25 citations in OpenAlex.
- Threshold effect of systemic immune-response index on in-stent neoatherosclerosis among patients with drug-eluting stent restenosis.European journal of medical research · 2025Article
- Drug-coated balloons for the treatment of in-stent restenosis: an updated systematic review and meta-analysis of randomized controlled trials.Annals of medicine and surgery (2012) · 2025Article
- Inhibitory effects on smooth muscle cell adhesion and proliferation due to oscillating electric fields by nanogenerators.Nanoscale · 2025Article
- Net meta-analysis: comparison of bare metal stent, drug-coated balloon and drug-eluting stent in the treatment of cerebral arterial stenosis.Frontiers in neurology · 2025Review
- TRIM27 Promotes Endothelial Progenitor Cell Apoptosis in Patients with In-Stent Restenosis by Ubiquitinating TBK1.Applied biochemistry and biotechnology · 2024Article
- Improved stent sharpness evaluation with super-resolution deep learning reconstruction in coronary CT angiography.The British journal of radiology · 2024Article
- Current Management of In-Stent Restenosis.Journal of clinical medicine · 2024Review
- Revascularization Modalities in Acute Coronary Syndrome: A Review of the Current State of Evidence.Cureus · 2023Review
- Drug-Coated Balloon in Primary Percutaneous Coronary Intervention.Journal of interventional cardiology · 2023Review
- Vascular restenosis reduction with platelet membrane coated nanoparticle directed M2 macrophage polarization.iScience · 2022Article
- Clinical outcomes of drug-coated balloon in coronary lesions: a real-world, all-comers study.Clinical research in cardiology : official journal of the German Cardiac Society · 2022Observational
- Incidence and risk factors of in-stent restenosis after percutaneous coronary intervention in patients from southern China.European journal of medical research · 2022Article
- miR-30b-5p Downregulation as a Predictive Biomarker of Coronary In-Stent Restenosis.Biomedicines · 2021Article
- Factors associated with temporary pacing insertion in patients with inferior ST-segment elevation myocardial infarction.PloS one · 2021Article
- Drug-coated balloon in patients with in-stent restenosis: A prospective observational study.Indian heart journalObservational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronary heart disease is a major cause of death and disability in developed countries. Stent implantation has become an efficacious treatment for a culprit lesion vessel of the coronary artery. However, 10%-20% restenosis is still an important complication that restricts the clinical safety and efficacy of drug-eluting stents. In-stent restenosis may lead to the recurrence of major cardiovascular adverse events, including angina pectoris, acute myocardial infarction, and even sudden cardiac death. These events are currently serious problems that occur after coronary stent implantation. Clinical physicians face a difficult choice for in-stent restenosis treatment. Recent studies indicate that a drug-coated balloon has promising clinical efficacy similar to the drug-eluting stents for treating coronary in-stent restenosis. Therefore, in this study, we highlight the progress of coronary intervention and the use of drug-coated balloons in the treatment of in-stent restenosis (ISR).
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.